Prima BioMed (NASDAQ:IMMP) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

Prima BioMed Ltd (NASDAQ:IMMP)’s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.44 and traded as low as $0.4205. Prima BioMed shares last traded at $0.4446, with a volume of 2,034,964 shares traded.

Prima BioMed News Summary

Here are the key news stories impacting Prima BioMed this week:

• Negative Sentiment: A class action lawsuit has been filed against Immutep Limited and certain officers, alleging federal securities law violations for investors who bought shares between March 24, 2025 and March 12, 2026. This raises legal overhang and uncertainty for the stock. Article: Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Multiple law firms published reminders about the July 6, 2026 lead-plaintiff deadline, signaling the lawsuit is active and keeping legal risk in focus for shareholders. Article: IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Additional alerts from The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Bernstein Liebhard, and SueWallSt all reiterated the pending class action, extending the negative news flow around IMMP. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Analysts Set New Price Targets

IMMP has been the topic of several analyst reports. Robert W. Baird downgraded shares of Prima BioMed from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $7.00 to $1.00 in a research report on Friday, March 13th. Citizens Jmp downgraded shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. Maxim Group downgraded shares of Prima BioMed from a “buy” rating to a “hold” rating in a research report on Friday, March 13th. Finally, Wall Street Zen raised shares of Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $5.50.

Prima BioMed Trading Down 1.3%

The stock’s 50-day moving average is $0.44 and its 200 day moving average is $1.78.

Prima BioMed (NASDAQ:IMMP) last announced its quarterly earnings data on Friday, January 30th. The biotechnology company reported ($0.10) EPS for the quarter. The company had revenue of $1.37 million for the quarter.

Institutional Trading of Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC grew its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.